Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma

The purpose of this study was to investigate the antitumor activity of regorafenib and sorafenib in preclinical models of HCC and to assess their mechanism of action by associated changes in protein expression in a HCC-PDX mouse model. Both drugs were administered orally once daily at 10 mg/kg (rego...

Descripción completa

Detalles Bibliográficos
Autores principales: Kissel, Maria, Berndt, Sandra, Fiebig, Lukas, Kling, Simon, Ji, Qunsheng, Gu, Qingyang, Lang, Tina, Hafner, Frank-Thorsten, Teufel, Michael, Zopf, Dieter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739799/
https://www.ncbi.nlm.nih.gov/pubmed/29291014
http://dx.doi.org/10.18632/oncotarget.22334

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739799/
https://www.ncbi.nlm.nih.gov/pubmed/29291014
http://dx.doi.org/10.18632/oncotarget.22334

Ejemplares similares